-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple comorbidities are common in type 2 diabetes mellitus (T2DM), and only about 14% of patients may not have other comorbidities
American Diabetes Association (ADA) guidelines recommend metformin (if noncontraindicated and tolerable) as the initial oral antiglycemic drug (OAD) of choice for the treatment of T2DM
It is unclear whether strict glycemic control in patients with COPD-T2DM improves coprogenic prognosis, but according to previous studies, poor glycemic control can exacerbate coprhage severity and clinical course
Investigators conducted cohort-based case-control studies using data from the Taiwan Provincial Health Insurance Research Database
In COPD-T2DM patients, 3355 patients with AECOPD and 13420 matching controls were selected
Relationship between OAD dual-drug therapy and AECOPD risk in patients with type 2 diabetes mellitus with COPD (n=12916)
Relationship between triple drug treatment of OAD and AECOPD risk in patients with type 2 diabetes mellitus with COPD (n=3859)
In simple terms, the results of this analysis show that in patients receiving a combination of two and three drugs for OAD, the addition of TZD reduces the risk of
Taken together, these results suggest that in patients with COPD-T2DM, combination therapy with TZDs is associated with a reduced risk of AECOPD, especially in people
References: 1.
2.